ScreenerHero

ARCTArcturus Therapeutics Holdings Inc.

NAS · US · Healthcare · Biotechnology · arcturusrx.com
13.45USD+30.84%Mkt Cap: 382.29M $P/E: —

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA techno…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap382.29M $
Enterprise Value143.82M $
Revenue (TTM)29.37M $
Gross Profit-57.41M $
Net Income (TTM)-65.78M $
Revenue/Share1.047 USD
Last Price13.45 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.96
PEG—
EV/EBITDA-1.45
EV/Revenue4.90
P/S10.64
P/B1.82
EPS (TTM)-3.57
EPS (Forward)-3.72
52W Range
5.50043% of range24.17
52W High24.17 USD
52W Low5.500 USD
Profitability
Gross Margin-195.50%
Oper. Margin-863.30%
EBITDA Margin0.00%
Profit Margin-97.86%
ROE-30.74%
ROA-24.26%
Growth
Revenue Growth-89.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.27M $
CapEx (TTM)230.00K $
FCF Margin65.58%
FCF Yield5.04%
Net Debt-168.55M $
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.12
Current Ratio5.88
Quick Ratio5.76
Book Value/Sh6.045 USD
Cash/Share6.737 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 16, 2017
Splits
Last Split1:7
Split DateNov 16, 2017
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.20 USD
Upside (mean)+50.2%
Target Range8.000 USD – 40.00 USD
$8.000+50.2% to mean$40.00
# Analysts10
Ownership
Shares Out.28.42M
Float26.15M
Insiders7.99%
Institutions83.08%
Short Interest
Short Ratio13.5d
Short % Float31.54%
Short % Out.25.36%
Shares Short7.21M
Short (prev mo.)6.80M
Technical
SMA 506.941 (+93.8%)
SMA 2007.368 (+82.6%)
Beta2.27
S&P 52W Chg18.16%
Avg Vol (30d)783.22K
Avg Vol (10d)1.38M
Technical Indicators
RSI (14)88.7
MACD0.9962
MACD Signal0.3548
MACD Hist.+0.6414
BB Upper10.97 USD
BB Middle7.120 USD
BB Lower3.272 USD
BB Width108.08%
ATR (14)0.8224 USD
Vol Ratio (20d)3.64x